cardiotomskСибирский журнал клинической и экспериментальной медициныSiberian Journal of Clinical and Experimental Medicine2713-29272713-265XTSU publishing10.29001/2073-8552-2022-37-3-56-64cardiotomsk-1503Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESНекоторые молекулярно-генетические факторы риска фиброза миокарда (обзор литературы)Some molecular genetic risk factors for myocardial fibrosis (Literature review)https://orcid.org/0000-0001-5937-4128ГриценкоО. В.GritsenkoO. V.

Гриценко Олеся Валерьевна, канд. мед. наук, врач кардиолог общебольничного отделения

656055, Барнаул, ул. Малахова, 46

Olesya V. Gritsenko, Cand. Sci. (Med.), Cardiologist, General Hospital Department

46, Malakhova str., Barnaul, 656055

qritzenko.olesia@mail.ruhttps://orcid.org/0000-0002-2810-6531ЧумаковаГ. А.ChumakovaG. A.

Чумакова Галина Александровна, д-р мед. наук, профессор, профессор кафедры терапии и общей врачебной практики

656000, Барнаул, пр. Ленина, 40

Galina A. Chumakova, Dr. Sci. (Med.), Professor, Department of Therapy and General Medical Practice

40, Lenina ave., Barnaul, 656000

g.a.chumakova@mail.ruhttps://orcid.org/0000-0002-3002-2863ПонасенкоА. В.PonasenkoA. V.

Понасенко Анастасия Валериевна, канд. мед. наук, заведующий лабораторией геномной медицины отдела экспериментальной медицины

650002, Кемерово, Сосновый б-р, 6

Anastasia V. Ponasenko, Cand. Sci. (Med.), Head of the Laboratory of Genomic Medicine, Division of Experimental Medicine

6, Sosnovy blvd., Kemerovo, 650002

avapanass@mail.ruhttps://orcid.org/0000-0002-7780-829XГруздеваО. В.GruzdevaO. V.

Груздева Ольга Викторовна, д-р мед. наук, заведующий лабораторией исследований гомеостаза отдела диагностики сердечно-сосудистых заболеваний

650002, Кемерово, Сосновый б-р, 6

Olga V. Gruzdeva, FSBI Research Institute for Complex Issues of Cardiovascular Diseases, head of the laboratory for homeostasis research department of diagnosis of cardiovascular diseases, MD

6, Sosnovy blvd., Kemerovo, 650002

o_gruzdeva@mail.ruАлтайский краевой кардиологический диспансерРоссияAltai Regional Cardiology DispensaryRussian FederationАлтайский государственный медицинский университет Министерства здравоохранения Российской ФедерацииРоссияAltai State Medical UniversityRussian FederationНаучно-исследовательский институт комплексных проблем сердечно-сосудистых заболеванийРоссияResearch Institute for Complex Issues of Cardiovascular DiseasesRussian Federation2022191020223735664Copyright © Гриценко О.В., Чумакова Г.А., Понасенко А.В., Груздева О.В., 20222022Гриценко О.В., Чумакова Г.А., Понасенко А.В., Груздева О.В.Gritsenko O.V., Chumakova G.A., Ponasenko A.V., Gruzdeva O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sibjcem.ru/jour/article/view/1503

Фиброз миокарда является многофакторным процессом, к которому предрасполагает ряд клеточных и молекулярных факторов, уровень которых детерминирован генетически. В данном обзоре рассмотрены некоторые генетические варианты, имеющие непосредственное отношение к развитию кардиофиброза и открывающие перспективы научных исследований по оценке риска сердечной недостаточности (СН) при различной сердечно-сосудистой патологии.

Myocardial fibrosis is a multifactorial process, which predisposes to a number of cellular and molecular factors, the level of which is determined genetically. This review discusses some genetic variants that are directly related to the development of cardiac fibrosis and open up prospects for scientific research on assessing the risk of heart failure in various cardiovascular pathologies.

фиброз миокардагенгенетическая вариабельностьсердечная недостаточностьmyocardial fibrosisgenegenetic variabilityheart failureReferencesГончарова И.А., Печерина Т.Б., Марков А.В., Кашталап В.В., Тарасенко Н.В., Пузырев В.П. и др. Роль генов фиброгенеза в формировании подверженности к коронарному атеросклерозу. Кардиология. 2018;58(8):33–44. DOI: 10.18087/cardio.2018.8.10160.Goncharova I.A., Pecherina T.B., Markov A.V., Kashtalap V.V., Tarasenko N.V., Puzyrev V.P. et al. Fibrogenesis genes and susceptibility to coronary atherosclerosis. Kardiologiia. 2018;58(8):33–44. (In Russ.) DOI: 10.18087/cardio.2018.8.10160.Ping K., Panagiota C., Frangogiannis N.G. The pathogenesis of сardiac fi brosis. Cell Mol. Life Sci. 2014;71(4): 549–574. DOI: 10.1007/s00018-013-1349-6.Ping K., Panagiota C., Frangogiannis N.G. The pathogenesis of сardiac fi brosis. Cell Mol. Life Sci. 2014;71(4): 549–574. DOI: 10.1007/s00018-013-1349-6.Asbun J., Villarreal F.J. The pathogenesis of myocardial fi brosis in the setting of diabetic cardiomyopathy. J. Am. Coll. Cardiol. 2006;47(4):693–700. DOI: 10.1016/j.jacc.2005.09.050.Asbun J., Villarreal F.J. The pathogenesis of myocardial fi brosis in the setting of diabetic cardiomyopathy. J. Am. Coll. Cardiol. 2006;47(4):693–700. DOI: 10.1016/j.jacc.2005.09.050.Bharati S., Lev M. Cardiac conduction system involvement in sudden death of obese young people. Am. Heart J. 1995;129(2):273–281. DOI: 10.1016/0002-8703(95)90008-x.Bharati S., Lev M. Cardiac conduction system involvement in sudden death of obese young people. Am. Heart J. 1995;129(2):273–281. DOI: 10.1016/0002-8703(95)90008-x.Печерина Т.Б., Кутихин А.Г. Биомаркеры фиброза миокарда и их генетическое регулирование у пациентов с сердечной недостаточностью. Российский кардиологический журнал. 2020;25(10):3933. DOI: 10.15829/1560- 4071-2020-3933.Pecherina T.B., Kutikhin A.G. Biomarkers of myocardial fi brosis and their genetic regulation in patients with heart failure. Russian Journal of Cardiology. 2020;25(10):3933. (In Russ.). DOI: 10.15829/1560-4071-2020-3933.Chan J.J., Tay Y. Noncoding RNA: RNA regulatory networks in cancer. Int. J. Mol. Sci. 2018;19(5):1310. DOI: 10.3390/ijms19051310.Chan J.J., Tay Y. Noncoding RNA: RNA regulatory networks in cancer. Int. J. Mol. Sci. 2018;19(5):1310. DOI: 10.3390/ijms19051310.Mattick J.S., Makunin I.V. Non-coding RNA. Hum. Mol. Genet. 2006;(1):R17–29. DOI: 10.1093/hmg/ddl046.Mattick J.S., Makunin I.V. Non-coding RNA. Hum. Mol. Genet. 2006;(1):R17–29. DOI: 10.1093/hmg/ddl046.Panni S., Lovering R.C., Porras P., Orchard S. Non-coding RNA regulatory networks. Biochim. Biophys. Acta Gene Regul. Mech. 2020;1863(6):194417. DOI: 10.1016/j.bbagrm.2019.194417.Panni S., Lovering R.C., Porras P., Orchard S. Non-coding RNA regulatory networks. Biochim. Biophys. Acta Gene Regul. Mech. 2020;1863(6):194417. DOI: 10.1016/j.bbagrm.2019.194417.Ramirez-Bello J., Jimenez-Morales M. Functional implications of single nucleotide polymorphisms (SNPs) in protein-coding and non-coding RNA genes in multifactorial diseases. Gac. Med. Mex. 2017;153(2):238–250.Ramirez-Bello J., Jimenez-Morales M. Functional implications of single nucleotide polymorphisms (SNPs) in protein-coding and non-coding RNA genes in multifactorial diseases. Gac. Med. Mex. 2017;153(2):238–250.Kwok Z.H., Tay Y. Long noncoding RNAs: Lincs between human health and disease. Biochem. Soc. Trans. 2017;45(3):805–812. DOI: 10.1042/BST20160376.Kwok Z.H., Tay Y. Long noncoding RNAs: Lincs between human health and disease. Biochem. Soc. Trans. 2017;45(3):805–812. DOI: 10.1042/BST20160376.Anastasiadou E., Jacob L.S., Slack F.J. Non-coding RNA networks in cancer. Nat. Rev. Cancer. 2018;18(1):5–18. DOI: 10.1038/nrc.2017.99.Anastasiadou E., Jacob L.S., Slack F.J. Non-coding RNA networks in cancer. Nat. Rev. Cancer. 2018;18(1):5–18. DOI: 10.1038/nrc.2017.99.Micheletti R., Plaisance I., Abraham B.J., Sarre A., Ching-Chia Ting, Alexanian M. et al. The long noncoding RNA Wisper controls cardiac fi brosis and remodeling. Sci. Transl. Med. 2017;9(395):eaai9118. DOI: 10.1126/scitranslmed.aai9118.Micheletti R., Plaisance I., Abraham B.J., Sarre A., Ching-Chia Ting, Alexanian M. et al. The long noncoding RNA Wisper controls cardiac fi brosis and remodeling. Sci. Transl. Med. 2017;9(395):eaai9118. DOI: 10.1126/scitranslmed.aai9118.Boon R.A., Dimmeler S. MicroRNAs in myocardial infarction. Nat. Rev. Cardiol. 2015;12(3):135–142. DOI: 10.1038/nrcardio.2014.207.Boon R.A., Dimmeler S. MicroRNAs in myocardial infarction. Nat. Rev. Cardiol. 2015;12(3):135–142. DOI: 10.1038/nrcardio.2014.207.Lu P., Ding F., Xiang Y.K., Hao L., Zhao M. Noncoding RNAs in Cardiac Hypertrophy and Heart Failure. Cells. 2022;11(5):777. DOI: 10.3390/cells11050777.Lu P., Ding F., Xiang Y.K., Hao L., Zhao M. Noncoding RNAs in Cardiac Hypertrophy and Heart Failure. Cells. 2022;11(5):777. DOI: 10.3390/cells11050777.Rooij E., Sutherland L.B., Liu N., Williams A.H., McAnally J., Gerard R.D. et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. U S A. 2006;103(48):18255–18260. DOI: 10.1073/pnas.0608791103.Rooij E., Sutherland L.B., Liu N., Williams A.H., McAnally J., Gerard R.D. et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. U S A. 2006;103(48):18255–18260. DOI: 10.1073/pnas.0608791103.Ilieva M., Miller H.E., Agarwal A., Paulus G.K., Madsen J.H., Bishop A.J.R. et al. FibroDB: Expression Analysis of Protein-Coding and Long Non-Coding RNA Genes in Fibrosis. Noncoding RNA. 2022;28;8(1):13. DOI: 10.3390/ncrna8010013.Ilieva M., Miller H.E., Agarwal A., Paulus G.K., Madsen J.H., Bishop A.J.R. et al. FibroDB: Expression Analysis of Protein-Coding and Long Non-Coding RNA Genes in Fibrosis. Noncoding RNA. 2022;28;8(1):13. DOI: 10.3390/ncrna8010013.Trinh K., Julovi S.M., Rogers N.M. The role of matrix proteins in cardiac pathology. Int. J. Mol. Sci. 2022;23(3):1338. DOI: 10.3390/ijms23031338.Trinh K., Julovi S.M., Rogers N.M. The role of matrix proteins in cardiac pathology. Int. J. Mol. Sci. 2022;23(3):1338. DOI: 10.3390/ijms23031338.Mohammadhosayni M., Khosrojerdi A., Lorian K., Aslani S., Imani D., Razi B. et al. Matrix metalloproteinases (MMPs) family gene polymorphisms and the risk of multiple sclerosis: Systematic review and meta- analysis. BMC Neurol. 2020;20(1):218. DOI: 10.1186/s12883-020-01804-2.Mohammadhosayni M., Khosrojerdi A., Lorian K., Aslani S., Imani D., Razi B. et al. Matrix metalloproteinases (MMPs) family gene polymorphisms and the risk of multiple sclerosis: Systematic review and meta- analysis. BMC Neurol. 2020;20(1):218. DOI: 10.1186/s12883-020-01804-2.Li T., Lv Z., Jing J.J., Yang J., Yuan Y. Matrix metalloproteinase family polymorphisms and the risk of aortic aneurysmal diseases: A systematic review and meta-analysis. Clin. Genet. 2018;93(1):15–32. DOI: 10.1111/cge.13050.Li T., Lv Z., Jing J.J., Yang J., Yuan Y. Matrix metalloproteinase family polymorphisms and the risk of aortic aneurysmal diseases: A systematic review and meta-analysis. Clin. Genet. 2018;93(1):15–32. DOI: 10.1111/cge.13050.Opstad T.B., Arnesen H., Pettersen A.Å., Seljefl ot I. The MMP-9 -1562 C/T polymorphism in the presence of metabolic syndrome increases the risk of clinical events in patients with coronary artery disease. 2014;9(9):e106816 DOI: 10.1371/journal.pone.0106816.Opstad T.B., Arnesen H., Pettersen A.Å., Seljefl ot I. The MMP-9 -1562 C/T polymorphism in the presence of metabolic syndrome increases the risk of clinical events in patients with coronary artery disease. 2014;9(9):e106816 DOI: 10.1371/journal.pone.0106816.Luizon M.R., Belo V.A., Fernandes K.S., Andrade V.L., Tanus-Santos J.E., Sandrim V.C. Plasma matrix metalloproteinase-9 levels, MMP-9 gene haplotypes, and cardiovascular risk in obese subjects. Mol. Biol. Rep. 2016;43(6):463–471. DOI: 10.1007/s11033-016-3993-z.Luizon M.R., Belo V.A., Fernandes K.S., Andrade V.L., Tanus-Santos J.E., Sandrim V.C. Plasma matrix metalloproteinase-9 levels, MMP-9 gene haplotypes, and cardiovascular risk in obese subjects. Mol. Biol. Rep. 2016;43(6):463–471. DOI: 10.1007/s11033-016-3993-z.DeLeon-Pennell K.Y., Meschiari C.A., Jung M., Lindsey M.L. Matrix metalloproteinases in myocardial infarction and heart failure. Prog. Mol. Biol. Transl. Sci. 2017;147:75–100. DOI: 10.1016/bs.pmbts.2017.02.001.DeLeon-Pennell K.Y., Meschiari C.A., Jung M., Lindsey M.L. Matrix metalloproteinases in myocardial infarction and heart failure. Prog. Mol. Biol. Transl. Sci. 2017;147:75–100. DOI: 10.1016/bs.pmbts.2017.02.001.Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ. Res. 2003;92(8):827–839. DOI: 10.1161/01.RES.0000070112.80711.3D.Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ. Res. 2003;92(8):827–839. DOI: 10.1161/01.RES.0000070112.80711.3D.Velho F.M., Cohen C.R., Santos K.G., Silvello D., Martinelli N., Biolo A. et al. Polymorphisms of matrix metalloproteinases in systolic heart failure: Role on disease susceptibility, phenotypic characteristics, and prognosis. J. Card. Fail. 2011;17(2):115–121. DOI: 10.1016/j.cardfail.2010.09.017.Velho F.M., Cohen C.R., Santos K.G., Silvello D., Martinelli N., Biolo A. et al. Polymorphisms of matrix metalloproteinases in systolic heart failure: Role on disease susceptibility, phenotypic characteristics, and prognosis. J. Card. Fail. 2011;17(2):115–121. DOI: 10.1016/j.cardfail.2010.09.017.Martin T.N., Penney D.E., Smith J.A., Groenning B.A., Dargie H.J., Hillis G.S. Matrix metalloproteinase-1 promoter polymorphisms and changes in left ventricular volume following acute myocardial infarction. Am. J. Cardiol. 2004;94(8):1044–1046. DOI: 10.1016/j.amjcard.2004.06.064.Martin T.N., Penney D.E., Smith J.A., Groenning B.A., Dargie H.J., Hillis G.S. Matrix metalloproteinase-1 promoter polymorphisms and changes in left ventricular volume following acute myocardial infarction. Am. J. Cardiol. 2004;94(8):1044–1046. DOI: 10.1016/j.amjcard.2004.06.064.Lindner D., Zietsch C., Becher P.M., Schulze K., Schultheiss H.P., Tschope C. et al. Diff erential expression of matrix metalloproteases in human fi broblasts with diff erent origins. Biochem. Res. Int. 2012;2012:875742. DOI: 10.1155/2012/875742.Lindner D., Zietsch C., Becher P.M., Schulze K., Schultheiss H.P., Tschope C. et al. Diff erential expression of matrix metalloproteases in human fi broblasts with diff erent origins. Biochem. Res. Int. 2012;2012:875742. DOI: 10.1155/2012/875742.Sage E.H., Reed M., Funk S.E., Truong T., Steadele M., Puolakkainen P. et al. Cleavage of the matricellular protein sparc by matrix metalloproteinase 3 produces polypeptides that infl uence angiogenesis. J. Biol. Chem. 2003;278(39):37849–37857. DOI: 10.1074/jbc.M302946200.Sage E.H., Reed M., Funk S.E., Truong T., Steadele M., Puolakkainen P. et al. Cleavage of the matricellular protein sparc by matrix metalloproteinase 3 produces polypeptides that infl uence angiogenesis. J. Biol. Chem. 2003;278(39):37849–37857. DOI: 10.1074/jbc.M302946200.Mashhadiabbas F., Neamatzadeh H., Foroughi E., Dastgheib S.A., Farahnak S., Nasiri R. et al. Association of MMP-2-753C>T and MMP-9-1562C>T Polymorphisms with Chronic/Aggressive Periodontitis Risk: A Systematic Review and Meta-Analysis. Iran. J. Public. Health. 2019;48(7):1227–1238.Mashhadiabbas F., Neamatzadeh H., Foroughi E., Dastgheib S.A., Farahnak S., Nasiri R. et al. Association of MMP-2-753C>T and MMP-9-1562C>T Polymorphisms with Chronic/Aggressive Periodontitis Risk: A Systematic Review and Meta-Analysis. Iran. J. Public. Health. 2019;48(7):1227–1238.Yabluchanskiy A., Ma Y., Iyer R.P., Hall M.E., Lindsey M.L. Matrix metalloproteinase-9: Many shades of function in cardiovascular disease. Physiology. 2013;28(6):391–403. DOI: 10.1152/physiol.00029.2013.Yabluchanskiy A., Ma Y., Iyer R.P., Hall M.E., Lindsey M.L. Matrix metalloproteinase-9: Many shades of function in cardiovascular disease. Physiology. 2013;28(6):391–403. DOI: 10.1152/physiol.00029.2013.Blankenberg S., Rupprecht H.J., Poirier O., Bickel C., Smieja M., Hafner G. et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascu-lar disease. Circulation. 2003;107(12):1579–1585. DOI: 10.1161/01.CIR.0000058700.41738.12.Blankenberg S., Rupprecht H.J., Poirier O., Bickel C., Smieja M., Hafner G. et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascu-lar disease. Circulation. 2003;107(12):1579–1585. DOI: 10.1161/01.CIR.0000058700.41738.12.Dai H., Chen L., Gao D., Fei A. Phosphocreatine attenuates isoproterenol-induced cardiac fibrosis and cardiomyocyte apoptosis. Biomed. Res. Int. 2019;2019:5408289. DOI: 10.1155/2019/5408289.Dai H., Chen L., Gao D., Fei A. Phosphocreatine attenuates isoproterenol-induced cardiac fibrosis and cardiomyocyte apoptosis. Biomed. Res. Int. 2019;2019:5408289. DOI: 10.1155/2019/5408289.Squire I.B., Evans J., Ng L.L., Loftus I.M., Thompson M.M. Plasma mmp-9 and mmp-2 following acute myocardial infarction in man: Correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. Journal of Cardiac Failure. 2004;10(4):328–333. DOI: 10.1016/j.cardfail.2003.11.003.Squire I.B., Evans J., Ng L.L., Loftus I.M., Thompson M.M. Plasma mmp-9 and mmp-2 following acute myocardial infarction in man: Correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. Journal of Cardiac Failure. 2004;10(4):328–333. DOI: 10.1016/j.cardfail.2003.11.003.Wang X., Shi L.Z. Association of matrix metalloproteinase-9 c1562t polymorphism and coronary artery disease: A meta-analysis. J. Zhejiang Univ. Sci. B. 2014;15(3):256–263. DOI: 10.1631/jzus.B1300088.Wang X., Shi L.Z. Association of matrix metalloproteinase-9 c1562t polymorphism and coronary artery disease: A meta-analysis. J. Zhejiang Univ. Sci. B. 2014;15(3):256–263. DOI: 10.1631/jzus.B1300088.Lacchini R., Metzger I.F., Luizon M., Ishizawa M., Tanus-Santos J.E. Interethnic differences in the distribution of matrix metalloproteinases genetic polymorphisms are consistent with interethnic differences in disease prevalence. DNA Cell Biol. 2010;29(11):649–655. DOI: 10.1089/dna.2010.1056.Lacchini R., Metzger I.F., Luizon M., Ishizawa M., Tanus-Santos J.E. Interethnic differences in the distribution of matrix metalloproteinases genetic polymorphisms are consistent with interethnic differences in disease prevalence. DNA Cell Biol. 2010;29(11):649–655. DOI: 10.1089/dna.2010.1056.Horwich T.B., Fonarow G.C. Glucose, obesity, metabolic syndrome, and diabetes relevance to Incidence of heart failure. J. Am. Coll. Cardiol. 2010;55(4):283–293. DOI: 10.1016/j.jacc.2009.07.029.Horwich T.B., Fonarow G.C. Glucose, obesity, metabolic syndrome, and diabetes relevance to Incidence of heart failure. J. Am. Coll. Cardiol. 2010;55(4):283–293. DOI: 10.1016/j.jacc.2009.07.029.Kremastiotis G., Handa I., Jackson C., George S., Johnson J. Disparate effects of MMP and TIMP modulation on coronary atherosclerosis and associated myocardial fibrosis. Sci. Rep. 2021;11(1):23081. DOI: 10.1038/s41598-021-02508-4.Kremastiotis G., Handa I., Jackson C., George S., Johnson J. Disparate effects of MMP and TIMP modulation on coronary atherosclerosis and associated myocardial fibrosis. Sci. Rep. 2021;11(1):23081. DOI: 10.1038/s41598-021-02508-4.Mazuchová J., Halašová E., Mazuch J., Šarlinová M., Valentová V., Franeková M. et al. Investigation of Association between Genetic Polymorphisms of MMP2, MMP8, MMP9 and TIMP2 and Development of Varicose Veins in the Slovak Population – Pilot Study. Physiol. Res. 2020;69(3):S443–S454. DOI: 10.33549/physiolres.934597.Mazuchová J., Halašová E., Mazuch J., Šarlinová M., Valentová V., Franeková M. et al. Investigation of Association between Genetic Polymorphisms of MMP2, MMP8, MMP9 and TIMP2 and Development of Varicose Veins in the Slovak Population – Pilot Study. Physiol. Res. 2020;69(3):S443–S454. DOI: 10.33549/physiolres.934597.Kandalam V., Basu R., Moore L., Fan D., Wang X., Jaworski D.M. et al. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress. Circulation. 2011;124(19):2094–2105. DOI: 10.1161/CIRCULATIONAHA.111.030338.Kandalam V., Basu R., Moore L., Fan D., Wang X., Jaworski D.M. et al. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress. Circulation. 2011;124(19):2094–2105. DOI: 10.1161/CIRCULATIONAHA.111.030338.Moore L., Fan D., Basu R., Kandalam V., Kassiri Z. Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Fail. Rev. 2012;17(4–5):693–706. DOI: 10.1007/s10741-011-9266-y.Moore L., Fan D., Basu R., Kandalam V., Kassiri Z. Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Fail. Rev. 2012;17(4–5):693–706. DOI: 10.1007/s10741-011-9266-y.Schanz M., Shi J., Wasser C., Alscher M.D., Kimmel M. Urinary [TIMP-2] × [IGFBP7] for risk prediction of acute kidney injury in decompensated heart failure. Clin. Cardiol. 2017;40:485–491. DOI: 10.1002/clc.22683.Schanz M., Shi J., Wasser C., Alscher M.D., Kimmel M. Urinary [TIMP-2] × [IGFBP7] for risk prediction of acute kidney injury in decompensated heart failure. Clin. Cardiol. 2017;40:485–491. DOI: 10.1002/clc.22683.Fan D., Takawale A., Basu R., Patel V., Lee J., Kandalam V. et al. Differential role of TIMP2 and TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction. Cardiovasc. Res. 2014;103(2):268–280. DOI: 10.1093/cvr/cvu072.Fan D., Takawale A., Basu R., Patel V., Lee J., Kandalam V. et al. Differential role of TIMP2 and TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction. Cardiovasc. Res. 2014;103(2):268–280. DOI: 10.1093/cvr/cvu072.Polina E.R., Araújo R.R.C.V., Sbruzzi R.C., Biolo A., Rohde L.E., Clausell N. et al. Relationship of polymorphisms in the tissue inhibitor of metalloproteinase (TIMP)-1 and -2 genes with chronic heart failure. Sci. Rep. 2018;8(1):9446. DOI: 10.1038/s41598-018-27857-5.Polina E.R., Araújo R.R.C.V., Sbruzzi R.C., Biolo A., Rohde L.E., Clausell N. et al. Relationship of polymorphisms in the tissue inhibitor of metalloproteinase (TIMP)-1 and -2 genes with chronic heart failure. Sci. Rep. 2018;8(1):9446. DOI: 10.1038/s41598-018-27857-5.Alp E., Yilmaz A., Tulmac M., Dikmen A.U., Cengel A., Yalcin R. et al. Analysis of MMP-7 and TIMP-2 gene polymorphisms in coronary artery disease and myocardial infarction: A Turkish case-control study. Kaohsiung J. Med. Sci. 2017;33(2):78–85. DOI: 10.1016/j.kjms.2016.12.002.Alp E., Yilmaz A., Tulmac M., Dikmen A.U., Cengel A., Yalcin R. et al. Analysis of MMP-7 and TIMP-2 gene polymorphisms in coronary artery disease and myocardial infarction: A Turkish case-control study. Kaohsiung J. Med. Sci. 2017;33(2):78–85. DOI: 10.1016/j.kjms.2016.12.002.Lin T.H., Chiu H.C., Lee Y.T., Su H.M., Juo S.H., Voon W.C. et al. The C-allele of tissue inhibitor of metalloproteinases 2 is associated with increased magnitude of QT dispersion prolongation in elderly Chinese – 4-year follow-up study. Clin. Chim. Acta. 2007;386(1–2):87–93. DOI: 10.1016/j.cca.2007.08.004.Lin T.H., Chiu H.C., Lee Y.T., Su H.M., Juo S.H., Voon W.C. et al. The C-allele of tissue inhibitor of metalloproteinases 2 is associated with increased magnitude of QT dispersion prolongation in elderly Chinese – 4-year follow-up study. Clin. Chim. Acta. 2007;386(1–2):87–93. DOI: 10.1016/j.cca.2007.08.004.Jia M., Li Z.B., Li L., Chu H.T., Li Z.Z. Role of matrix metalloproteinase‑7 and apoptosis‑associated gene expression levels in the pathogenesis of atrial fibrosis in a Beagle dog model. Mol. Med. Rep. 2017;16(5):6967–6973. DOI: 10.3892/mmr.2017.7415.Jia M., Li Z.B., Li L., Chu H.T., Li Z.Z. Role of matrix metalloproteinase‑7 and apoptosis‑associated gene expression levels in the pathogenesis of atrial fibrosis in a Beagle dog model. Mol. Med. Rep. 2017;16(5):6967–6973. DOI: 10.3892/mmr.2017.7415.Dong H., Dong S., Zhang L., Gao X., Lv G., Chen W. et al. MicroRNA-214 exerts a Cardio-protective effect by inhibition of fibrosis. Anat. Rec. (Hoboken). 2016;299(10):1348–1357. DOI: 10.1002/ar.23396.Dong H., Dong S., Zhang L., Gao X., Lv G., Chen W. et al. MicroRNA-214 exerts a Cardio-protective effect by inhibition of fibrosis. Anat. Rec. (Hoboken). 2016;299(10):1348–1357. DOI: 10.1002/ar.23396.Lu Y., Boer J.M.A., Barsova R.M., Favorova O., Goel A., Müller M. et al. TGFB1 genetic polymorphisms and coronary heart disease risk: A meta-analysis. BMC Med. Genet. 2012;13:39. DOI: 10.1186/1471-2350-13-39.Lu Y., Boer J.M.A., Barsova R.M., Favorova O., Goel A., Müller M. et al. TGFB1 genetic polymorphisms and coronary heart disease risk: A meta-analysis. BMC Med. Genet. 2012;13:39. DOI: 10.1186/1471-2350-13-39.Gichkun O.E., Shevchenko O.P., Kurabekova R.M., Mozheiko N.P., Shevchenko A.O. The rs1800470 polymorphism of the TGFB1 gene is associated with myocardial fibrosis in heart transplant recipients. Acta Naturae. 2021;13(4):42–46. DOI: 10.32607/actanaturae.11469.Gichkun O.E., Shevchenko O.P., Kurabekova R.M., Mozheiko N.P., Shevchenko A.O. The rs1800470 polymorphism of the TGFB1 gene is associated with myocardial fibrosis in heart transplant recipients. Acta Naturae. 2021;13(4):42–46. DOI: 10.32607/actanaturae.11469.Shah R., Hurley C.K., Posch P.E. A molecular mechanism for the differential regulation of TGF-beta1 expression due to the common SNP -509C-T (c. -1347C>T). Hum. Genet. 2006;120(4):461–469. DOI: 10.1007/s00439-006-0194-1.Shah R., Hurley C.K., Posch P.E. A molecular mechanism for the differential regulation of TGF-beta1 expression due to the common SNP -509C-T (c. -1347C>T). Hum. Genet. 2006;120(4):461–469. DOI: 10.1007/s00439-006-0194-1.Barsova R.M., Titov B.V., Matveeva N.A., Favorov A.V., Sukhinina T.S., Shahnovich R.M. et al. Contribution of the TGFB1 gene to myocardial infarction susceptibility. Acta Naturae. 2012;4(2):74–79.Barsova R.M., Titov B.V., Matveeva N.A., Favorov A.V., Sukhinina T.S., Shahnovich R.M. et al. Contribution of the TGFB1 gene to myocardial infarction susceptibility. Acta Naturae. 2012;4(2):74–79.Брусенцов Д.А., Никулина С.Ю., Шестерня П.А., Чернова А.А. Ассоциация полиморфных вариантов RS1800470 гена трансформирующего ростового фактора β1 (TGF-β1) с тяжестью коронарного атеросклероза. Российский кардиологический журнал. 2018;(10):43–47. DOI: 10.15829/1560-4071-2018-10-43-47. Brusentsov D.A., Nikulina S.Yu., Shesternya P.A., Chernova A.A. Association of RS1800470 polymorphic variants of the transforming growth factor β1 (TGF-β1) gene with the severity of coronary atherosclerosis. Russian Journal of Cardiology. 2018;(10):43–47. (In Russ.). DOI: org/10.15829/1560-4071-2018-10-43-47.Брусенцов Д.А., Никулина С.Ю., Шестерня П.А., Чернова А.А. Ассоциация полиморфных вариантов RS1800470 гена трансформирующего ростового фактора β1 (TGF-β1) с тяжестью коронарного атеросклероза. Российский кардиологический журнал. 2018;(10):43–47. DOI: 10.15829/1560-4071-2018-10-43-47. Brusentsov D.A., Nikulina S.Yu., Shesternya P.A., Chernova A.A. Association of RS1800470 polymorphic variants of the transforming growth factor β1 (TGF-β1) gene with the severity of coronary atherosclerosis. Russian Journal of Cardiology. 2018;(10):43–47. (In Russ.). DOI: org/10.15829/1560-4071-2018-10-43-47.Crobu F., Palumbo L., Franco E., Bergerone S., Carturan S., Guarrera S. et al. Role of TGF-β1 haplotypes in the occurrence of myocardial infarction in young Italian patients. BMC Med. Genet. 2008;9:13. DOI: 10.1186/1471-2350-9-13.Crobu F., Palumbo L., Franco E., Bergerone S., Carturan S., Guarrera S. et al. Role of TGF-β1 haplotypes in the occurrence of myocardial infarction in young Italian patients. BMC Med. Genet. 2008;9:13. DOI: 10.1186/1471-2350-9-13.Liu S., Ke W., Liu Y., Zhao Z., An L., You X. et al. Function analysis of differentially expressed microRNAs in TGF-β1-induced cardiac fibroblasts differentiation. Biosci. Rep. 2019;39(10):BSR20182048. DOI: 10.1042/BSR20182048.Liu S., Ke W., Liu Y., Zhao Z., An L., You X. et al. Function analysis of differentially expressed microRNAs in TGF-β1-induced cardiac fibroblasts differentiation. Biosci. Rep. 2019;39(10):BSR20182048. DOI: 10.1042/BSR20182048.Cocciolone A.J., Hawes J.Z., Staiculescu M.C., Johnson E.O., Murshed M., Wagenseil J.E. Elastin, arterial mechanics, and cardiovascular disease. Am. J. Physiol. Heart Circ. Physiol. 2018;315(2):H189–H205. DOI: 10.1152/ajpheart.00087.2018.Cocciolone A.J., Hawes J.Z., Staiculescu M.C., Johnson E.O., Murshed M., Wagenseil J.E. Elastin, arterial mechanics, and cardiovascular disease. Am. J. Physiol. Heart Circ. Physiol. 2018;315(2):H189–H205. DOI: 10.1152/ajpheart.00087.2018.Tassabehji M., Metcalfe K., Donnai D., Hurst J., Reardon W., Burch M. et al. Elastin: Genomic structure and point mutations in patients with supravalvular aortic stenosis. Hum. Mol. Genet. 1997;6:1029–1036. DOI: 10.1093/hmg/6.7.1029.Tassabehji M., Metcalfe K., Donnai D., Hurst J., Reardon W., Burch M. et al. Elastin: Genomic structure and point mutations in patients with supravalvular aortic stenosis. Hum. Mol. Genet. 1997;6:1029–1036. DOI: 10.1093/hmg/6.7.1029.Li S.H., Sun Z., Guo L., Han M., Wood M.F., Ghosh N. et al. Elastin overexpression by cell-based gene therapy preserves matrix and prevents cardiac dilation. J. Cell Mol. Med. 2012;16(10):2429–2439. DOI: 10.1111/j.1582-4934.2012.01560.x.Li S.H., Sun Z., Guo L., Han M., Wood M.F., Ghosh N. et al. Elastin overexpression by cell-based gene therapy preserves matrix and prevents cardiac dilation. J. Cell Mol. Med. 2012;16(10):2429–2439. DOI: 10.1111/j.1582-4934.2012.01560.x.

The authors declare that there are no conflicts of interest present.